Compare LFMD & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | SIGA |
|---|---|---|
| Founded | 1994 | 1995 |
| Country | United States | United States |
| Employees | 384 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.1M | 230.2M |
| IPO Year | N/A | 2016 |
| Metric | LFMD | SIGA |
|---|---|---|
| Price | $3.82 | $3.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.14 | N/A |
| AVG Volume (30 Days) | 679.7K | ★ 768.8K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.52 | N/A |
| Revenue Next Year | $18.73 | $224.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.60 | $3.01 |
| 52 Week High | $7.32 | $9.62 |
| Indicator | LFMD | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 33.81 |
| Support Level | $3.39 | $3.01 |
| Resistance Level | $4.19 | $4.84 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 42.63 | 16.67 |
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.